Trial Profile
Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Advanced Solid Tumors ( Phase I )
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Talazoparib (Primary) ; Talazoparib
- Indications Solid tumours
- Focus Adverse reactions
- 27 Mar 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 25 Sep 2022 Planned initiation date changed from 10 Nov 2021 to 10 Nov 2022.
- 25 Sep 2022 Planned End Date changed from 1 May 2023 to 10 Jan 2024.